Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.
[esophageal adenocarcinoma]
It
has
previously
been
shown
that
gefitinib-treated
patients
with
epidermal
growth
factor
receptor
(
EGFR
)
gene
amplification
or
high
polysomy
had
a
statistically
significant
improvement
in
response
,
time
to
progression
,
and
survival
in
non-
small
cell
lung
cancer
(
NSCLC
)
.
Only
few
studies
utilizing
anti-
EGFR
treatment
in
advanced
esophageal
adenocarcinomas
have
been
performed
and
the
results
have
been
heterogeneous
.
The
aim
of
this
study
was
to
evaluate
EGFR
-targeted
therapy
with
gefitinib
in
esophageal
adenocarcinoma
with
a
high
EGFR
polysomy
.
Novel
esophageal
cell
lines
PT
6216
and
LN
6216
c
were
established
from
primary
tumor
and
lymph
node
metastasis
of
a
patient
with
highly
aggressive
and
metastatic
adenocarcinoma
.
Pathological
examination
including
tumor
differentiation
and
prognostic
marker
analysis
,
immunohistochemical
EGFR
expression
analysis
,
EGFR
fluorescence
in
situ
hybridization
,
and
mutation
analysis
were
performed
.
Response
of
novel
cell
lines
to
gefitinib
treatment
was
evaluated
by
cell
proliferation
and
vitality
assays
.
Fifty
-
four
esophageal
adenocarcinoma
specimens
were
evaluated
for
EGFR
gene
copy
gain
.
The
primary
tumor
cell
line
PT
6216
and
the
lymph
node
cell
line
LN
6216
c
show
a
homogenously
high
polysomy
for
EGFR
determined
by
FISH
analysis
.
Cell
proliferation
and
vitality
are
highly
sensitive
to
the
tyrosine
kinase
inhibitor
gefitinib
compared
to
esophageal
control
cells
without
a
high
polysomy
for
EGFR
.
High
polysomy
for
EGFR
was
found
in
35
%
of
patients
.
We
show
for
the
first
time
a
significant
treatment
response
to
the
EGFR
tyrosine
kinase
inhibitor
gefitinib
in
esophageal
tumor
cells
with
a
high
polysomy
for
EGFR
,
suggesting
a
future
role
of
anti-
EGFR
therapy
for
esophageal
adenocarcinoma
patients
with
a
high
EGFR
polysomy
.
Diseases
Validation
Diseases presenting
"statistically significant improvement in response"
symptom
esophageal adenocarcinoma
esophageal carcinoma
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom